Loading patent…
AssigneeGenentech, Inc.
InventorsPriti HEGDE, Marcin KOWANETZ, Gregg FINE, Sanjeev MARIATHASAN, Richard BOURGON
Estimating the term…
The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on expression levels of a biomarker of the invention (e.g., PD-L1 expression levels in tumor-infiltrating immune cells in a tumor sample obtained from the patient) and/or based on the determination of a tumor sample subtype.
(canceled)
A kit comprising reagents for measuring the mRNA expression level of FGFR3, CDKN2A, KRT5, KRT14, EGFR, GATA3, FOXA1, ERBB2, or a combination thereof.
A method of treating a patient suffering from a bladder cancer, the method comprising administering to the patient a therapeutically effective amount of atezolizumab, wherein a tumor sample obtained from the patient has been determined to have a detectable expression level of PD-L1 in tumor-infiltrating immune cells that comprise about 5% or more of the tumor sample, and wherein the tumor sample obtained from the patient has been determined to be a TCGA basal subtype tumor.
Dependencies are inferred from the claim text.